Mohammed Haneefa Nizamudeen/iStock via Getty Images Black Diamond Therapeutics ( NASDAQ: BDTX ), a clinical-stage oncology company, said on Monday that it is undertaking a corporate restructuring to focus resources on advancing lead program BDTX-1535 into pivotal development, and to extend the company’s expected cash runway into Q2.
Back to Health Page
